top of page

Press Releases

5
June
2023

Lirum Therapeutics Presents Data on LX-101, A Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers

New York, NY – June 5, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 7th Cancer World Congress in Palermo, Italy... 

8
Feb
2023

Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock

New York, NY – February 8, 2023 – Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses...

bottom of page